Boston Scientific sees higher-than-expected 2025 profit on strong demand
Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.
Boston Scientific sees FY25 adjusted EPS $2.80-$2.87, consensus $2.81
The company said, “The company estimates net sales growth for the full year 2025, versus the prior year period, to be in a range of approximately 12.5 to 14.5 percent on a reported basis, and ...
Boston Scientific price target raised to $115 from $95 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on Boston Scientific (BSX) to $115 from $95 and keeps an Overweight rating on ...